Clinical trials: Vascular Endothelial Growth Factor
Age-related Macular Degeneration, Diabetic Macular Edema
Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor.
- Conditions
- Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02118831
- Testing
- Blood Sample Collection, Aflibercept, Bevacizumab
- Volunteers
- 56 people
- Sponsor
- California Retina Consultants
Choroidal Neovascularization (CNV)
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
This study was conducted to evaluate the efficacy and safety of 0.5 mg ranibizumab in adult and adolescent patients with visual impairment due to choridal neovascularization (CNV).
- Trial name
- NCT01840410
- Testing
- Ranibizumab
- Where
- 59 sites in Australia, Canada and 19 more
- Volunteers
- 183 people
- Sponsor
- Novartis Pharmaceuticals
Vascular Anomaly, Generalized Lymphatic Anomaly
Identification of Biomarkers for Patients with Vascular Anomalies
The study will use blood (serum and plasma) and tissue obtained from participants undergoing prescribed surgical resection of vascular anomalies of interest proposed in this study.
- Conditions
- Vascular Anomaly, Generalized Lymphatic Anomaly, Kaposiform Hemangioendothelioma, Kaposiform Lymphangiomatosis
- Trial name
- NCT03001180
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Macular Edema, Cystoid, Uveitis
Vascular Endothelial Growth Factor (VEGF) in Uveitis
This study will look for the presence in blood of a substance called vascular endothelial growth factor (VEGF) in patients with uveitis (eye inflammation).
- Trial name
- NCT00001738
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Renal Function Disorder, Diabetic Macular Edema (DME)
Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients.
- Conditions
- Renal Function Disorder, Diabetic Macular Edema (DME), Neovascular Age Related Macular Degeneration
- Trial name
- NCT06929507
- Testing
- Intravitreal injection of Faricimab or Aflibercept 2 mg
- Where
- 2 sites in Greece
- Volunteers
- 60 people
- Sponsor
- University Hospital, Alexandroupolis
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Periodontal Diseases
Thiol/Disulphide Homeostasis and Vascular Endothelial Growth Factor Levels in Diabetic Children
The aim of this study to evaluate the vascular endothelial growth factor level and thiol/disulphide homeostasis in saliva of diabetic children with gingivitis.
- Trial name
- NCT04470635
- Testing
- ELISA
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Aydin Adnan Menderes University
Wet AMD
Genetics Study of Wet Age-Related Macular Degeneration (AMD) Non-Responders to Vascular Endothelial Growth Factor (VEGF) Therapy
To obtain a genotypic analysis of patients with chronic exudative age-related macular degeneration noted to have subretinal or intraretinal edema despite continuous monthly Anti-VEGF therapy.
- Trial name
- NCT01310686
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West Coast Retina Medical Group, Inc.
Metastatic Colorectal Cancer
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer
This is a clinical trial investigating the effectiveness and safety of the combination of the study drugs bevacizumab and AMG386 in patients with advanced (metastatic) chemotherapy-naive bowel (colorectal) cancer.
- Trial name
- Vengeance (NCT01249521)
- Testing
- AMG386 and bevacizumab
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Austin Health
Retinopathy of Prematurity
Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP)
The purpose of this study is to determine whether a single intravitreal (into the gel of the eye) injection of Avastin 0.625mg or 0.75mg is equivalent (non-inferior) to treatment with standard of care laser in infants with Type I…
- Trial name
- BLOCK-ROP (NCT01232777)
- Testing
- Bevacizumab
- Where
- 19 sites in United States, Canada
- Sponsor
- Vision Research Foundation
Osteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
This study adopts a novel strategy for first-line treatment of osteosarcoma by combining chemotherapy with anti-angiogenic therapy using bevacizumab (Avastin®), a humanized monoclonal antibody against vascular endothelial growth…
- Trial name
- NCT00667342
- Testing
- Bevacizumab, Cisplatin, Doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- St. Jude Children's Research Hospital
Macular Edema (ME)
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
To evaluate the efficacy and safety of 0.5 mg Ranibizumab intravitreal injections in adult patients with visual impairment due to macular edema (ME).
- Trial name
- NCT01846299
- Testing
- Ranibizumab
- Where
- 61 sites in Australia, Belgium and 17 more
- Volunteers
- 181 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carcinoma
Recurrence and Distant Metastases in Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization
This project will include at least 40 patients with hepatocellular carcinoma (HCC) who will receive transcatheter arterial chemoembolization (TACE) as a sole method for the management.
- Trial name
- NCT00834028
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Differentiated Thyroid Cancer
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
The objective of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid…
- Trial name
- NCT03690388
- Testing
- Cabozantinib
- Where
- 164 sites in United States, Argentina and 23 more
- Volunteers
- 187 people
- Sponsor
- Exelixis
Type 1 Diabetes
Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel Formation
The aim of the study is to see how glycaemic control and glycaemic variability affect levels of HIF, VEGF, erythropoietin and cortisol in Paediatric Type 1 diabetics on insulin pump therapy.
- Trial name
- INDIGO 2 (NCT01429467)
- Testing
- Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)
- Where
- United Kingdom
- Volunteers
- 35 people
- Sponsor
- University of Dundee
Infant, Premature, Diseases
Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab
To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab
- Trial name
- NCT03115255
- Testing
- intravitreal ranibizumab
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Retinopathy of Prematurity
Oral Propranolol Versus Placebo for Early Stages of Retinopathy of Prematurity: A Randomized and Prospective Study
In premature infants, propranolol (Prop) treatment might suppress continuing neo-vascularization (NV) and decelerate the progression of retinopathy of prematurity (ROP) towards its severe stages (III-V), thus avoiding the need of…
- Trial name
- NCT01238471
- Testing
- propranolol, sucrose 5%
- Where
- 4 sites in Israel
- Volunteers
- 20 people
- Sponsor
- Rambam Health Care Campus
Renal Cell Carcinoma, Kidney Cancer
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma
The goal of this clinical research study is to learn if the combination of 3 drugs (gemcitabine, capecitabine, and bevacizumab) can help to control metastatic or unresectable renal cell carcinoma.
- Trial name
- NCT00496587
- Testing
- Capecitabine, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Retinopathy of Prematurity
Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity
Retinopathy of Prematurity (ROP) is a leading cause of blindness in children in developed countries around the world, and an increasing cause of blindness in developing countries. The retina lines the inside of the eye.
- Trial name
- BLOCK-ROP (NCT00702819)
- Testing
- Bevacizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 2 people
- Sponsor
- Vision Research Foundation
Diabetic Retinopathy
Blood Factors and Diabetic Retinopathy
This study will determine whether certain factors in the blood are associated with the severity of diabetic retinopathy. Patients age 10 years and older with diabetes mellitus and diabetic retinopathy may be eligible for this…
- Trial name
- NCT00005761
- Where
- United States
- Volunteers
- 173 people
- Sponsor
- National Eye Institute (NEI)